RPAM
OCUL icon

Rhenman & Partners Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Rhenman & Partners Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.58M Buy
305,000
+40,000
+15% +$381K 0.32% 76
2025
Q4 		$3.22M Buy
265,000
+63,000
+31% +$765K 0.3% 76
2025
Q3 		$2.36M Buy
+202,000
New +$2.42M 0.26% 82
2017
Q3 		– Sell
-40,000
Closed -$371K – 103
2017
Q2 		$371K Hold
40,000
– – 0.05% 95
2017
Q1 		$371K Hold
40,000
– – 0.06% 93
2016
Q4 		$335K Hold
40,000
– – 0.06% 93
2016
Q3 		$275K Hold
40,000
– – 0.04% 96
2016
Q2 		$198K Hold
40,000
– – 0.04% 95
2016
Q1 		$386K Buy
+40,000
New +$303K 0.08% 90

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return